Australia's most trusted
source of pharma news
">
Posted 31 October 2025 PM
The spectacular fall from grace for Organon boss Kevin Ali who stepped down from the CEO role over improper sales practices was our top story this week.
Ali walked away with no severance or equity-related retirement benefits after an internal investigation revealed the company, under his stewardship, asked certain wholesalers to buy more of the company's birth control implant than they needed over multiple quarters to enable Organon to meet guidance expectations.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.